Lantern Pharma Inc.
Lantern Pharma Inc. (LTRN) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
ltrn · stock forecast · 3 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 3 Wall Street analysts in the past 3 months
Buy
3 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $3.75
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $3.94 | ↑ 5.00% |
1-day model range: $3.88–$3.99. Peak: $3.99 (+5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $3 | -28.5% |
| 2028 | $2 | -38.6% |
| 2029 | $2 | -43.0% |
| 2030 | $2 | -45.0% |
| 2031 | — | -46.0% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · LTRN · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-08-10 | EF Hutton | Maintains | Buy→Buy |
| 2023-06-26 | EF Hutton | Maintains | Buy→Buy |
| 2023-05-18 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2023-03-21 | EF Hutton | Maintains | Buy→Buy |
| 2023-02-15 | EF Hutton | Maintains | Buy→Buy |
| 2022-11-01 | EF Hutton | Maintains | Buy→Buy |
| 2022-03-11 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2021-11-02 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2021-10-07 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2020-07-28 | Colliers Securities | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Lantern Pharma Inc. (LTRN) stock. Of the recent 10 rating actions, 0 were upgrades and 0 were downgrades. 3 analysts currently cover LTRN.
Analyst Recommendation Trends
LTRN analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$2M
↓ 94.2% YoY
Revenue Next Year
$15M
↑ 648.7% YoY
EPS This Year
$-1.51
EPS Next Year
$-2.02
↑ 33.8% YoY
EPS ForecastReported vs Estimated
Analysts forecast LTRN EPS of $-1.51 for the current fiscal year, based on estimates from 1 analysts. The LTRN revenue forecast is $2M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The LTRN stock forecast is supported by two independent data sources: analyst consensus ratings from 3 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus LTRN price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The LTRN short-term stock prediction for tomorrow is $3.94 (+5.00%). The LTRN stock price prediction for 2027 estimates an average of $3. The LTRN stock prediction for 2030 projects a range of $2–$2.
Lantern Pharma Inc. trades on NASDAQ under the ticker LTRN. The LTRN stock outlook for 2027 is broadly positive, supported by a Buy consensus among 67% of covering analysts.
Frequently asked questions
LTRN forecast · 8 questionsAccording to 3 Wall Street analysts, the average 12-month LTRN price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $3.75.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.